Connect with us

Business

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Published

on

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?
ET Intelligence Group: Symbiotec Pharmalab plans to raise ₹150 crore through a fresh issue to repay debt and ₹1,607 crore through an offer for sale. The promoter group’s stake will fall to 33.3% after the IPO from 36.4%. The company is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.Over two-third of the revenue comes from international markets with Europe contributing nearly 30%. Top five products contribute nearly 63% to revenue, signalling product concentration. The valuation is attractive compared with peers. Given these factors and market leadership in some of the products, investors with high-risk appetite may apply for the long-term.
Symbiotec’s API Edge Makes a Long-term Case, Risk Riders ApplyAgencies

Product concentration is a watchpoint, valuation a draw

Business

Incorporated in 2002, Symbiotec Pharmalab has a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms in FY26, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs According to Frost & Sullivan. It was the only company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in FY26. The company has a backward-integrated platform with approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. APIs continue to be the primary revenue driver, contributing more than 96% to total revenue in FY26, while newer initiatives such as complex injectables and contract manufacturing (CDMO) offerings make up the balance. As of FY26, the company operated two API manufacturing facilities and commissioned two additional plants, expanding fermentation capacity to 700 KL and adding complex injectables capacity of 20 million vials annually.

Financials

Between FY24 and FY26, revenue from operations grew 10.2% annually to ₹869.1 crore, operating profit before interest, tax, depreciation and amortization (EBITDA) increased 14.5% to ₹232 crore and net profit rose 4.8% to 109.9 crore. While EBITDA margin expanded to 26.6% in FY26 from 24.5% in FY24, operating cash flow remained volatile, rising to ₹174.6 crore in FY26 from ₹47.3 crore in FY25, compared with ₹187.5 crore in FY24. It reflects heavy capital expenditure and fluctuations in working capital, particularly inventory and trade payables.Read more: Pride Hotels steps up expansion, plans Rs 1,000-cr IPO by December

Advertisement

Valuation

Symbiotec lacks an exact listed peer due to a niche in steroidal hormones and advanced drug-device formulation. Considering the post-IPO equity and net profit for FY26, the company demands a price-earnings (P/E) multiple of up to 58. For other API or biotechnology manufacturers such as Concord Biotech, Divi’s Laboratories, Cohance Lifesciences and Laurus Labs, the P/E range is between 63 and 110.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Henderson precinct finalised, cost not revealed

Published

on

Henderson precinct finalised, cost not revealed

Nuclear-powered submarine sustainment operations will sit in the middle of the Henderson precinct, flanked by non-defence operations, under finalised site plans presented by the Prime Minister in Perth today.

Continue Reading

Business

ASX 200 Rises as Miners Rally and Ampol Profit Surges During Reporting Season’s Final Week as Banks Lag

Published

on

Australia Housing Market 2026: Two-Speed Boom Persists as Prices Hit

SYDNEY — The S&P/ASX 200 climbed 42.8 points, or 0.47%, to 9,101.7 as of 2:58 p.m. AEST Monday, as strength across the mining sector and a standout profit result from fuel retailer Ampol offset weakness in banks and insurers heading into the final week of Australia’s corporate earnings season.

The benchmark opened the session only marginally higher, up just 0.1% to 9,071 points at 10:15 a.m. AEST, according to ABC News’ live market coverage, with miners in the basic materials sector and healthcare stocks leading the early gains while banks and insurers weighed on the index by weighting. By 11 a.m., the ASX 200 had extended its advance to 0.6%, reaching 9,110 points, with the broader All Ordinaries index posting a similar gain as big miners continued to drive the session’s momentum.

Fuel retailer Ampol delivered one of the standout results of the morning, with its integrated business model capitalizing on global product market dislocation to deliver a profit surge well ahead of analyst expectations. According to Market Index’s live coverage, Ampol’s replacement cost operating profit EBITDA rose 152% to $1.637 billion, beating Macquarie’s estimate of $1.603 billion by 2%, while replacement cost operating profit EBIT climbed 245% to $1.392 billion, a 3% beat, driven largely by the company’s Fuels and Infrastructure division, which surged 859% to $1.135 billion as its Lytton refinery swung to a $533.4 million contribution from just $1.1 million the prior year. Ampol’s replacement cost net profit after tax rose 376%, according to the same report.

Regional lender Bendigo and Adelaide Bank also reported results Monday, posting full-year statutory profit of $375 million, in line with analyst estimates. On the bank’s preferred cash earnings metric, which strips out one-off gains and losses, profit rose a modest 3.0% to $530.2 million against estimates of $532 million, while second-half cash earnings of $273.8 million matched forecasts of $274 million almost precisely, according to Market Index. ABC News reported that second-half momentum showed greater strength specifically, with cash earnings up 7% to $274 million for that period.

Advertisement

Lithium miner Pilbara Minerals delivered one of the day’s more dramatic turnaround stories, reporting a full-year profit of $526 million after posting an almost $200 million loss the previous year. According to ABC News, sales revenue jumped 150% to almost $2 billion, driven in large part by a 120% increase in realized prices over the year. The company kept costs lower and will pay a full-year dividend of 5 cents per share, having skipped a dividend payment entirely the previous year.

Quick-service restaurant operator Guzman y Gomez drew renewed analyst attention Monday following its recent earnings result. According to The Motley Fool Australia, Bell Potter downgraded the stock to a hold rating with an improved price target of $27.30, even as the broker praised the company’s underlying performance. “While we think GYG is a clear leader in the QSR space after displaying strong comp sales growth, margin expansion, and further network growth opportunities, we see near-term cost headwinds and a consumer slow-down as a risk to FY27 guidance and view the current multiple as fairly valued. While we increase our PT ~11%, it is only a modest premium to the share price, so we downgrade to HOLD,” Bell Potter said.

Alcohol retailer Endeavour Group also featured prominently in Monday’s earnings coverage, with management fielding investor questions about the durability of retail momentum and softening trade at its hotels division. According to Market Index, the company addressed its planned $100 million in cost reductions for fiscal 2027, noting that wage growth for the coming year is “quite materially elevated, and therefore the AUD 100 million of cost out will go to largely offset it, but will not drive more than an offset.” Management also cautioned that the strong 4.6% start to retail sales in the new fiscal year had been flattered by heavy promotional activity, saying, “I hadn’t seen a 20% off before, and hopefully we don’t s—,” a comment cut off in the live coverage transcript. The company reported inventory down 11% to $24.1 million and a net cash position of $5.2 million, having repaid all borrowings, while noting fiscal 2027-to-date same-store sales across Australia and New Zealand were up 11.4% over the first seven weeks, even as online sales declined 8% amid reduced promotional activity.

Gold miners were positioned for a strong start to the week, with Capricorn Metals and other gold-exposed names expected to benefit from continued strength in the precious metal, according to The Motley Fool Australia’s preview of Monday’s session. Meanwhile, early trading saw oil prices slip roughly 1%, or about $1 a barrel, across key global benchmarks, while gold prices edged higher.

Advertisement

Investors are now heading into the final week of the current August reporting season, a stretch ABC News described as likely to prompt analysts to trim some earnings forecasts, even though the season overall has been far from disastrous. Discretionary spending-focused stocks have faced a particularly difficult stretch throughout the reporting period, and this week’s calendar includes further releases from consumer-facing companies including Wesfarmers, Harvey Norman, Qantas and Domino’s Pizza, all of which could produce significant share price swings depending on how their results land relative to expectations. Coles is also scheduled to report this week, according to ABC News’ preview of the coming sessions.

Numerous stocks traded ex-dividend Monday, a technical adjustment that tends to weigh modestly on individual share prices independent of broader market sentiment, according to ABC News’ market notes.

With the ASX 200 continuing to trade well below its all-time high of 9,198.6 points reached in February, but having recovered meaningfully from its closer-to-8,800 level in July, investors are likely to remain focused for the remainder of the week on how the final wave of major consumer, retail and travel-sector earnings reports shapes the index’s trajectory heading into September, as the current reporting season draws to its conclusion.

Advertisement
Continue Reading

Business

GDEV Inc earnings matched, revenue fell short of estimates

Published

on


GDEV Inc earnings matched, revenue fell short of estimates

Continue Reading

Business

Ansell Limited (ANSLY) Q4 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript